Evaluation of the Efficacy of the Composite WM Formula in Promoting GLP-1 Secretion

Launched by TCI CO., LTD. · Jul 30, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a special dietary supplement called the WM Formula to see if it can help increase levels of a natural hormone called GLP-1, which plays a role in controlling blood sugar and may support weight management. The study is focused on adults who have higher body fat levels and aims to understand how this supplement affects their body’s ability to regulate blood sugar.

To take part, adults 18 years or older with a body fat percentage of 30% or more for women, or 25% or more for men, may be eligible. Women who are pregnant or breastfeeding cannot join, and participants should not be using certain medications or supplements related to diabetes, weight loss, or gut health before starting. During the study, participants will visit the clinic twice, with about a week between visits. Each visit will last around 5 hours and include blood tests, body measurements, and questionnaires. Blood samples will be taken multiple times before and after taking the WM Formula or water to track its effects. This careful process helps researchers learn if the supplement could be a helpful option for managing obesity and blood sugar control.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults aged 18 years or older who are willing to sign the informed consent form.
• • Body fat percentage: ≥30% for females and ≥25% for males.
• • Non-pregnant and non-lactating women who agree to use physical contraceptive methods (e.g., condoms, intrauterine devices) throughout the study period.
• Exclusion Criteria:
• • Use of GLP-1 receptor agonists approved in Taiwan (e.g., liraglutide, semaglutide, dulaglutide), blood glucose-regulating medications, weight loss-related drugs or functional foods, probiotics, or gastrointestinal health-related supplements or medications within 30 days prior to the start of the study.
• • History of chronic gastrointestinal disorders, seizure disorders or epilepsy, hepatic or renal diseases, malignancies, endocrine disorders, psychiatric illnesses, alcohol or drug abuse, or other major organic diseases based on medical history.
• • History of gastrointestinal surgery, organ transplantation, or other major surgeries.
• • History of hypoglycemia.
• • Known lactose intolerance.
• • Chronic diarrhea.
• • Acute gastroenteritis within 2 weeks prior to study initiation.
• • Known allergy to any ingredient in the investigational product.
• • Employees or immediate family members of TCI Co., Ltd.